Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus

Archives of Pharmacal Research

Volumn 37, Issue 5, 2014, Pages 671-678

  Ha, Tae Young ^a   Kim, Young Seok ^a   Kim, Chun Hwa ^a   Choi, Hyo Sun ^a   Yang, Jin ^a   Park, Soo Hyun ^b   Kim, Dae Hoon ^a   Rhee, Jae Keol ^a  

^a Dongkook Pharm Co Ltd   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Body weight; cAMP; GLP 1; GPR119 agonist

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; HD 0471042; INSULIN; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GPR119 PROTEIN, HUMAN; GPR119 PROTEIN, MOUSE; GPR119 PROTEIN, RAT; HD0471042; OXADIAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; WEIGHT GAIN; AGONISTS; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; RAT; STRUCTURE ACTIVITY RELATION; TIME;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; CHO CELLS; CRICETULUS; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE, INBRED C57BL; OBESITY; OXADIAZOLES; PIPERIDINES; RATS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRANSFECTION; WEIGHT GAIN;

EID: 84901280258     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0209-0     Document Type: Article

References (17)

1. Chu, Z.L., C. Carroll, J. Alfonso, V. Gutierrez, H. He, A. Lucman, M. Pedraza, H. Mondala, H. Gao, D. Bagnol, R. Chen, R.M. Jones, D.P. Behan, and J. Leonard. 2008. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149(5): 2038-2047. (Pubitemid 351574507)
2. Chu, Z.L., C. Carroll, R. Chen, J. Alfonso, V. Gutierrez, H. He, A. Lucman, C. Xing, K. Sebring, J. Zhou, B. Wagner, D. Unett, R.M. Jones, D.P. Behan, and J. Leonard. 2010. N-Oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Molecular Endocrinology 24(1): 161-170.
3. Chu, Z.L., R.M. Jones, H. He, C. Carroll, V. Gutierrez, A. Lucman, M. Moloney, H. Gao, H. Mondala, D. Bagnol, D. Unett, Y. Liang, K. Demarest, G. Semple, D.P. Behan, and J. Leonard. 2007. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148(6): 2601-2609. (Pubitemid 46984798)
4. Felber, J.P., and A. Golay. 2002. Pathways from obesity to diabetes. International Journal of Obesity and Related Metabolic Disorders 26(suppl 2): S39-S45. (Pubitemid 35034486)
5. Henquin, J.C. 2000. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49(11): 1751-1760.
6. Kesty, N.C., J.D. Roth, and D. Maggs. 2008. Hormone-based therapies in the regulation of fuel metabolism and body weight. Expert Opinion on Biological Therapy 8(11): 1733-1747.
7. Madiraju, S.R., and V. Poitout. 2007. G protein-coupled receptors and insulin secretion: 119 and counting. Endocrinology 148(6): 2598-2600. (Pubitemid 46984778)
8. Ohishi, T., and S. Yoshida. 2012. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 21(3): 321-328.
9. Prokopenko, I., M.I. McCarthy, and C.M. Lindgren. 2008. Type 2 diabetes: new genes, new understanding. Trends in Genetics 24(12): 613-621.
10. Sadry, S.A., and D.J. Drucker. 2013. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nature Reviews Endocrinology 9: 425-433.
11. Sakamoto, Y., H. Inoue, S. Kawakami, K. Miyawaki, T. Miyamoto, K. Mizuta, and M. Itakura. 2006. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochemical and Biophysical Research Communications 351(2): 474-480. (Pubitemid 44666712)
12. Semple, G., B. Fioravanti, G. Pereira, I. Calderon, J. Uy, K. Choi, Y. Xiong, A. Ren, M. Morgan, V. Dave, W. Thomsen, D.J. Unett, C. Xing, S. Bossie, C. Carroll, Z.L. Chu, A.J. Grottick, E.K. Hauser, J. Leonard, and R.M. Jones. 2008. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. Journal of Medicinal Chemistry 51(17): 5172-5175.
13. Singh, S., H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, and J.B. Segal. 2013. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study. JAMA Internal Medicine 173(7): 534-539.
14. Stumvoll, M., B.J. Goldstein, and T.W. van Haeften. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365(9467): 1333-1346.
15. Turton, M.D., D. O'Shea, I. Gunn, S.A. Beak, C.M. Edwards, K. Meeran, S.J. Choi, G.M. Taylor, M.M. Heath, P.D. Lambert, J.P. Wilding, D.M. Smith, M.A. Ghatei, J. Herbert, and S.R. Bloom. 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560): 69-72. (Pubitemid 26008136)
16. Yoshida, S., T. Ohishi, T. Matsui, H. Tanaka, H. Oshima, Y. Yonetoku, and M. Shibasaki. 2010. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochemical and Biophysical Research Communications 402(2): 280-285.
17. Yoshida, S., T. Ohishi, T. Matsui, H. Tanaka, H. Oshima, Y. Yonetoku, and M. Shibasaki. 2011. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic beta-cell function. Diabetes, Obesity and Metabolism 13(1): 34-41.